RecruitingPHASE1, PHASE2NCT04315324
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
Studying Acute lymphoblastic leukemia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- SWOG Cancer Research Network
- Principal Investigator
- Anjali S AdvaniSWOG Cancer Research Network
- Intervention
- AKR1C3-activated Prodrug AST-3424(drug)
- Enrollment
- 67 enrolled
- Eligibility
- 12 years · All sexes
- Timeline
- 2021 – 2028
Study locations (30)
- University of Alabama at Birmingham Cancer Center, Birmingham, Alabama, United States
- Kingman Regional Medical Center, Kingman, Arizona, United States
- Arkansas Children's Hospital, Little Rock, Arkansas, United States
- PCR Oncology, Arroyo Grande, California, United States
- City of Hope Comprehensive Cancer Center, Duarte, California, United States
- Loma Linda University Medical Center, Loma Linda, California, United States
- Children's Hospital of Orange County, Orange, California, United States
- Children's Hospital Colorado, Aurora, Colorado, United States
- Alfred I duPont Hospital for Children, Wilmington, Delaware, United States
- Golisano Children's Hospital of Southwest Florida, Fort Myers, Florida, United States
- Memorial Regional Hospital/Joe DiMaggio Children's Hospital, Hollywood, Florida, United States
- Johns Hopkins All Children's Hospital, St. Petersburg, Florida, United States
- Emory University Hospital/Winship Cancer Institute, Atlanta, Georgia, United States
- Children's Healthcare of Atlanta - Arthur M Blank Hospital, Atlanta, Georgia, United States
- Augusta University Medical Center, Augusta, Georgia, United States
- +15 more locations on ClinicalTrials.gov
Collaborators
National Cancer Institute (NCI)
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT04315324 on ClinicalTrials.govOther trials for Acute lymphoblastic leukemia
Additional recruiting or active studies for the same condition.
- RECRUITINGNANCT05621291A Study to Evaluate Next-Generation Sequencing (NGS) Testing and Monitoring of B-cell Recovery to Guide Management Following Chimeric Antigen Receptor T-cell (CART) Induced Remission in Children and Young Adults With B Lineage Acute Lymphoblastic Leu...National Cancer Institute (NCI)
- ENROLLING BY INVITATIONNCT07511959Autologous Exosomes From Platelet-rich Plasma as a Modern Tool of Regenerative DentistryWroclaw Medical University
- RECRUITINGPHASE2NCT06738368Etoposide, Prednisone, Vincristine, Cyclophosphamide, and Doxorubicin (DA-EPOCH) With or Without Rituximab Plus Recombinant Erwinia Asparaginase (JZP458) for the Treatment of Newly Diagnosed Ph Negative B-Acute Lymphoblastic Leukemia or T Acute Lymphoblastic LeukemiaUniversity of Washington
- RECRUITINGNANCT07191119Transcutaneous Auricular Vagus Nerve Stimulation for Insomnia in Survivors of Childhood Acute Lymphoblastic LeukemiaSt. Jude Children's Research Hospital
- RECRUITINGPHASE2NCT07275762Y-4 to Treat the Postherpetic NeuralgiaNeurodawn Pharmaceutical Co., Ltd.
- RECRUITINGNANCT07177183Low Serum Creatinine as a Predictor of Prolonged Mechanical Ventilation and Weaning FailureUniversity Hospital Ostrava
- ENROLLING BY INVITATIONNCT07515430The Association Between Gut Microbiome Composition Signature and Cancer-related Symptoms in Children With Acute Lymphoblastic LeukemiaSun Yat-sen University
- RECRUITINGNANCT07201974Virtual Reality for Post-Stroke Gait RehabilitationMcGill University